![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, April 11, 2008 10:05:01 AM
http://www.pinksheets.com/pink/quote/quote.jsp?symbol=crvr
Columbia River Resources Inc.'s Traxxec Ltd. delivers New Sales Channels and Maximises Route to Market
Apr 11, 2008 (EWORLDWIRE via Comtex) -- Traxxec Ltd., the U.K. subsidiary of Columbia River Resources Inc. (Pink Sheets: CRVR), has opened new sales channels selling directly to the clinical trial and contract market. As part of the tertiary stage of its re-organisation, the company has negotiated a policy with Rexam plc that allows it to sell directly into the pharmaceutical clinical trial arena, and to pharmaceutical contract and clinical research organisations. These are market sectors in which Traxxec holds considerable expertise. Initially offering lower volumes per contract, the sales are more suited to the approach of a systems integration company such as Traxxec. With licenced partner Rexam focusing on volume sales to the high volume manufacturing facilities, Traxxec can bring additional sales by expanding the new channels.
It has been reported previously that Traxxec has already implemented pilot studies and directly supplied product in this arena both in the U.S. and in Europe. The companies' management teams feels that the most efficient way to leverage the opportunity is to ensure first-to-market status, establish a market share, and continually stay one step ahead through evolution and innovation of the product concept.
Product development is now complete, IP protected and manufacturing out-licensed by agreement. Key focus for the coming quarter will be efficiency and volume of new and existing routes to market. Traxxec has the necessary expertise and knowledge to deliver infrastructure solutions, allowing the new direct sales channels to include the possible sale, design and implementation of systems to the end user is outside of the license agreement with Rexam.
CEO Amy Scopes comments, "With previous experience of supplying packaging systems expertise to companies such as Glaxo Smith Kline and AstraZeneca and Pfizer, we are delighted open up these new sales channels. They represent a specialist sector of our business expansion plan and revenue generation. We believe our previous strong performance in this arena will be of significant benefit in the expansion of this sector."
Columbia River Resources Inc. will be filing to change the corporate name to Traxxec Inc. as the completion of its reorganisation.
For more information visit 'http://www.Traxxec.com'.
NOTES:
1. Traxxec's technology has worldwide patent protection
2. As part of the proposed business model and product development process, the founders of Traxxec, funded by the pharmaceutical industry, have undertaken through two pilot installations, a feasibility study on product design and as a consequence of this work, supplied a fully commercial product for evaluation purposes to a client with an annual buying capacity of 20,000,000 bottles. Traxxec Ltd. was incorporated specifically to exploit this IP commercially. Since its incorporation, Traxxec Ltd has also supplied commercial product for a live, current Phase III study in the U.S. As part of the technology transfer to Rexam Pharma, commercial product was successfully manufactured by the company and supported by systems software provided by Traxxec Ltd. To date 21,000 units have been delivered.
3. The result of the comprehensive testing led to the decision by Rexam to enter into licensing negotiation and complete the 15-year royalty licence agreement. The market sector for pharmaceutical product is in excess of USD$20 billion and bottles represent 30 percent of the available market per annum.
4. Traxxec has commercial arrangements with Assa Abloy identification Technologies, a Swiss-based global leader in the supply of packaged RFID component parts, and with Telsonic Ultrasonics for current and further product development work.
5. With the global patent and the relationship with Rexam, its first licence contract, the company is ideally positioned to deliver this potential within this very lucrative market, with revenues from both product sales and system integrations as well as revenues form any further development products in line with its business model.
This news release contains forward-looking statements that are subject to certain risks and uncertainties that may cause actual results to differ materially from those projected on the basis of such forward-looking statements. The words "estimate," "project," "intends," "expects," "believes," and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management's beliefs, as well as assumptions made by, and information currently available to, management pursuant to the"safe-harbour" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made, and the company undertakes no obligation to disclose any revision to these forward-looking statements to reflect events or circumstances after the date made or to reflect the occurrence of unanticipated events.
HTML: http://www.eworldwire.com/pressreleases/18391
PDF: http://www.eworldwire.com/pdf/18391.pdf
ONLINE NEWSROOM: http://www.eworldwire.com/newsroom/313072.htm
RSS NEWSROOM: http://newsroom.eworldwire.com/xml/newsrooms/313072.xml
Source: Traxxec Limited
CONTACT: Marie Mear
Traxxec Limited
138, Hassell Street
Newcastle under Lyme
Staffordshire, ST5 1BB
PHONE. 0845 396 8168
EMAIL: enquiries@traxxec.com
http://www.traxxec.com
Recent BRTX News
- BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 06/17/2024 11:05:00 AM
- Shares of Biotech MicroCap Rip on Licensing Talks • AllPennyStocks.com • 06/13/2024 03:40:00 PM
- BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program • GlobeNewswire Inc. • 06/13/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 06/11/2024 08:28:30 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 06/11/2024 08:23:50 PM
- BioRestorative Therapies, Inc. to attend the Jefferies 2024 Healthcare Conference • GlobeNewswire Inc. • 06/04/2024 12:50:00 PM
- BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice • GlobeNewswire Inc. • 05/24/2024 11:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 08:51:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 08:45:27 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/16/2024 09:17:17 PM
- BioRestorative Therapies Provides First Quarter 2024 Business Update • GlobeNewswire Inc. • 05/14/2024 08:10:00 PM
- BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity • GlobeNewswire Inc. • 05/08/2024 11:30:00 AM
- BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 • GlobeNewswire Inc. • 04/30/2024 08:15:00 PM
- BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technology • GlobeNewswire Inc. • 04/30/2024 11:30:00 AM
- Biotech Catches Major Premarket Bid Following FDA Clearance • AllPennyStocks.com • 04/16/2024 02:25:00 PM
- BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment • GlobeNewswire Inc. • 04/16/2024 11:45:00 AM
- BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease • GlobeNewswire Inc. • 04/08/2024 11:45:00 AM
- BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants • GlobeNewswire Inc. • 04/03/2024 08:38:00 PM
- BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K • GlobeNewswire Inc. • 04/01/2024 11:45:00 AM
- BioRestorative Therapies to Participate in the 36th Annual ROTH Conference • GlobeNewswire Inc. • 03/11/2024 08:15:00 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 03/06/2024 09:34:22 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/15/2024 09:43:54 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/15/2024 09:40:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:27:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:25:23 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM